DE2950995C2 - - Google Patents
Info
- Publication number
- DE2950995C2 DE2950995C2 DE2950995A DE2950995A DE2950995C2 DE 2950995 C2 DE2950995 C2 DE 2950995C2 DE 2950995 A DE2950995 A DE 2950995A DE 2950995 A DE2950995 A DE 2950995A DE 2950995 C2 DE2950995 C2 DE 2950995C2
- Authority
- DE
- Germany
- Prior art keywords
- dna
- hepatitis
- virus
- hybrid
- hvb
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 108020004414 DNA Proteins 0.000 claims description 105
- 239000013598 vector Substances 0.000 claims description 38
- 239000012634 fragment Substances 0.000 claims description 29
- 241000700721 Hepatitis B virus Species 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 17
- 102000053602 DNA Human genes 0.000 claims description 16
- 108091008146 restriction endonucleases Proteins 0.000 claims description 9
- 210000002966 serum Anatomy 0.000 claims description 9
- 238000001514 detection method Methods 0.000 claims description 8
- 239000002773 nucleotide Substances 0.000 claims description 5
- 125000003729 nucleotide group Chemical group 0.000 claims description 5
- 210000004369 blood Anatomy 0.000 claims description 4
- 239000008280 blood Substances 0.000 claims description 4
- 239000002243 precursor Substances 0.000 claims description 4
- 239000012472 biological sample Substances 0.000 claims description 3
- 210000002381 plasma Anatomy 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 108090000623 proteins and genes Proteins 0.000 description 16
- 102000004169 proteins and genes Human genes 0.000 description 10
- 241000894006 Bacteria Species 0.000 description 9
- 239000000427 antigen Substances 0.000 description 8
- 102000036639 antigens Human genes 0.000 description 8
- 108091007433 antigens Proteins 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 239000002245 particle Substances 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 208000002672 hepatitis B Diseases 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 238000013519 translation Methods 0.000 description 6
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 5
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 238000010367 cloning Methods 0.000 description 5
- 102000012410 DNA Ligases Human genes 0.000 description 4
- 108010061982 DNA Ligases Proteins 0.000 description 4
- 108010042407 Endonucleases Proteins 0.000 description 4
- 102000004533 Endonucleases Human genes 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 108091027305 Heteroduplex Proteins 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000001962 electrophoresis Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 241001515965 unidentified phage Species 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- 108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 3
- 239000011543 agarose gel Substances 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 108020004638 Circular DNA Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 108020004682 Single-Stranded DNA Proteins 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000001631 haemodialysis Methods 0.000 description 2
- 230000000322 hemodialysis Effects 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 238000005199 ultracentrifugation Methods 0.000 description 2
- 101150069452 z gene Proteins 0.000 description 2
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108020004485 Nonsense Codon Proteins 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108010059712 Pronase Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 101000874347 Streptococcus agalactiae IgA FC receptor Proteins 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- YTRQFSDWAXHJCC-UHFFFAOYSA-N chloroform;phenol Chemical compound ClC(Cl)Cl.OC1=CC=CC=C1 YTRQFSDWAXHJCC-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 238000004049 embossing Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 206010019692 hepatic necrosis Diseases 0.000 description 1
- 230000007866 hepatic necrosis Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- QYSGYZVSCZSLHT-UHFFFAOYSA-N octafluoropropane Chemical compound FC(F)(F)C(F)(F)C(F)(F)F QYSGYZVSCZSLHT-UHFFFAOYSA-N 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000033458 reproduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/706—Specific hybridization probes for hepatitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Communicable Diseases (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR7835588A FR2444713A1 (fr) | 1978-12-18 | 1978-12-18 | Procede de production d'un adn comprenant le genome du virus de l'hepatite b et vecteur le comportant |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE2950995A1 DE2950995A1 (de) | 1980-07-24 |
| DE2950995C2 true DE2950995C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1991-05-02 |
Family
ID=9216265
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19792950995 Granted DE2950995A1 (de) | 1978-12-18 | 1979-12-18 | Verfahren zur herstellung einer dna, welche das genom des hepatitis b virus sowie den vektor umfasst, der dieses genom enthaelt |
Country Status (6)
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2480779B2 (fr) * | 1979-08-30 | 1986-07-18 | Anvar | Vecteur contenant une sequence nucleotidique de l'antigene de surface du virus de l'hepatite b et procede de fabrication d'une molecule immunogene mettant en oeuvre ce vecteur |
| IE53176B1 (en) * | 1978-12-22 | 1988-08-17 | Biogen Nv | Recombinant dna molecules and their method of production |
| EP0182442B2 (en) * | 1978-12-22 | 1996-04-03 | Biogen, Inc. | Recombinant DNA molecules and their method of production |
| US6270955B1 (en) | 1978-12-22 | 2001-08-07 | Biogen, Inc. | Pharmaceutical compositions and methods for producing antibodies to hepatitis b virus and kits and methods for detecting antibodies to hepatitis b virus |
| IE52036B1 (en) * | 1979-05-24 | 1987-05-27 | Univ California | Non-passageable viruses |
| US5196194A (en) * | 1979-05-24 | 1993-03-23 | The Regents Of The University Of California | Vaccines containing Hepatitis B S-protein |
| US6835557B1 (en) | 1980-01-08 | 2004-12-28 | Biogen, Inc. | DNA sequences, recombinant DNA molecules and processes for producing human interferon-like polypeptides |
| US4530901A (en) * | 1980-01-08 | 1985-07-23 | Biogen N.V. | Recombinant DNA molecules and their use in producing human interferon-like polypeptides |
| EP0038765B1 (fr) * | 1980-04-22 | 1987-09-02 | Institut Pasteur | Vaccin contre l'hépatite virale B, procédé et cellules eucaryotes transformées pour la production de ce vaccin |
| US4393133A (en) * | 1980-06-12 | 1983-07-12 | The Wistar Institute Of Anatomy And Biology | Human hepatoma derived cell line, process for preparation thereof, and uses therefor |
| US5145782A (en) * | 1980-12-08 | 1992-09-08 | The Regents Of The University Of California | DNA expression vector suitable for direct expression of a foreign gene |
| US4446237A (en) * | 1981-03-27 | 1984-05-01 | Life Technologies, Inc. | Method for detection of a suspect viral deoxyribonucleic acid in an acellular biological fluid |
| EP0062286A1 (en) * | 1981-03-31 | 1982-10-13 | Albert Einstein College Of Medicine Of Yeshiva University | Diagnostic test for hepatitis B virus |
| US4711955A (en) * | 1981-04-17 | 1987-12-08 | Yale University | Modified nucleotides and methods of preparing and using same |
| US4769238A (en) | 1981-08-04 | 1988-09-06 | The Regents Of The University Of California | Synthesis of human virus antigens by yeast |
| US4803164A (en) * | 1981-08-31 | 1989-02-07 | Genentech, Inc. | Preparation of hepatitis b surface antigen in yeast |
| ZW18282A1 (en) | 1981-08-31 | 1983-03-23 | Genentech Inc | Preparation of polypeptides in vertebrate cell culture |
| AU8746582A (en) * | 1981-09-02 | 1983-03-10 | Biogen N.V. | Hepatitis b virus e type antigen |
| FI63596C (fi) * | 1981-10-16 | 1983-07-11 | Orion Yhtymae Oy | Mikrobdiagnostiskt foerfarande som grundar sig pao skiktshybridisering av nukleinsyror och vid foerfarandet anvaenda kombinationer av reagenser |
| US4480040A (en) * | 1981-12-03 | 1984-10-30 | The United States Of America As Represented By The Secretary Of Agriculture | Sensitive and rapid diagnosis of viroid diseases and viruses |
| JPS5931799A (ja) * | 1982-08-16 | 1984-02-20 | Science & Tech Agency | Ｂ型肝炎ウイルス遺伝子を組込んだ組換えプラスミド |
| US4699877A (en) * | 1982-11-04 | 1987-10-13 | The Regents Of The University Of California | Methods and compositions for detecting human tumors |
| USRE35491E (en) * | 1982-11-04 | 1997-04-08 | The Regents Of The University Of California | Methods and compositions for detecting human tumors |
| US4820642A (en) * | 1983-04-04 | 1989-04-11 | The Regents Of The University Of California | Amplified expression vector |
| FR2560995B1 (fr) * | 1984-03-07 | 1988-02-19 | Pasteur Institut | Reactifs et necessaires pour le dosage quantitatif d'un acide nucleique viral dans un milieu biologique et procede de dosage de cet acide nucleique viral |
| US5780036A (en) * | 1991-08-26 | 1998-07-14 | The Scripps Research Institute | Peptides for inducing cytotoxic T lymphocyte responses to hepattis B virus |
| US6607727B1 (en) | 1991-08-26 | 2003-08-19 | The Scripps Research Institute | Peptides for inducing cytotoxic T lymphocyte responses to hepatitus B virus |
| EP0618924B1 (en) * | 1991-12-23 | 2001-02-14 | Bayer Corporation | Hbv amplifier probes for use in solution phase sandwich hybridization assays |
| US6235288B1 (en) | 1992-08-26 | 2001-05-22 | The Scripps Research Institute | Peptides for inducing cytotoxic T lymphocyte responses to hepatitis B virus |
| CN1370238A (zh) | 1999-06-16 | 2002-09-18 | 艾科斯有限公司 | 人聚(adp－核酸)聚合酶2的物质和方法 |
| WO2002046208A2 (en) | 2000-11-01 | 2002-06-13 | Elusys Therapeutics, Inc. | Method of producing biospecific molecules by protein trans-splicing |
| WO2006119266A2 (en) | 2005-04-29 | 2006-11-09 | Rockefeller University | Human micrornas and methods for inhibiting same |
| WO2007028047A2 (en) | 2005-09-01 | 2007-03-08 | Celgene Corporation | Immunological uses of immunodulatory compounds for vaccine and anti-infections disease therapy |
| NZ616254A (en) | 2007-06-27 | 2015-04-24 | Us Sec Dep Of Health And Human Services | Complexes of il-15 and il-15ralpha and uses thereof |
| EP2324044A4 (en) | 2008-08-04 | 2012-04-25 | Univ Miami | STING (STIMULATOR OF INTERFERON GENES) AS A REGULATOR OF BORROWING IMMUNE REACTIONS |
| US8691502B2 (en) | 2008-10-31 | 2014-04-08 | Tremrx, Inc. | T-cell vaccination with viral vectors via mechanical epidermal disruption |
| WO2010085660A2 (en) | 2009-01-23 | 2010-07-29 | Roger Williams Hospital | Viral vectors encoding multiple highly homologous non-viral polypeptides and the use of same |
| US9216189B2 (en) | 2010-01-25 | 2015-12-22 | Icahn School Of Medicine At Mount Sinai | Antibodies which bind type I cannabinoid receptor/angiotensis II receptor heteromers |
| WO2012151272A2 (en) | 2011-05-02 | 2012-11-08 | Tremrx, Inc. | T-cell vaccination with viral vectors via mechanical epidermal disruption |
| CN104302304A (zh) | 2012-02-16 | 2015-01-21 | 宾西法利亚州研究基金会 | 脂酰辅酶a溶血心磷脂酰基转移酶1(alcat1)的调节剂及其用途 |
| JP6486272B2 (ja) | 2012-09-07 | 2019-03-20 | マサチューセッツ・アイ・アンド・イア・インファーマリー | 有毛細胞および／または支持細胞再生のための方法および組成物 |
| AU2013334610B2 (en) | 2012-10-24 | 2018-09-13 | Novartis Ag | IL-15R alpha forms, cells expressing IL-15R alpha forms, and therapeutic uses of IL-15R alpha and IL-15/IL-15R alpha complexes |
| ES2811974T3 (es) | 2014-07-29 | 2021-03-15 | Novartis Ag | Regímenes de aumento escalonado de la dosis del heterodímero de il-15 e il-15ralfa para tratar afecciones |
| WO2016069906A1 (en) | 2014-10-29 | 2016-05-06 | Massachusetts Eye And Ear Infirmary | Efficient delivery of therapeutic molecules to cells of the inner ear |
| US10258697B2 (en) | 2014-10-29 | 2019-04-16 | Massachusetts Eye And Ear Infirmary | Efficient delivery of therapeutic molecules in vitro and in vivo |
| US12239699B2 (en) | 2018-09-11 | 2025-03-04 | Shanghai Public Health Clinical Center | Immunogen for broad-spectrum influenza vaccine and application thereof |
| US11786592B2 (en) | 2021-05-19 | 2023-10-17 | The University Of Hong Kong | Compositions of cardiolipin adjuvants and methods of use thereof |
| WO2023077147A2 (en) | 2021-11-01 | 2023-05-04 | Pellis Therapeutics, Inc. | T-cell vaccines for patients with reduced humoral immunity |
| WO2023220283A1 (en) | 2022-05-12 | 2023-11-16 | Pellis Therapeutics, Inc. | Poxvirus adjuvant for t-cell vaccination |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1521032A (en) * | 1974-08-08 | 1978-08-09 | Ici Ltd | Biological treatment |
| DE2712615A1 (de) * | 1977-03-18 | 1978-09-21 | Max Planck Gesellschaft | Verfahren zur herstellung von filamentoesen phagen als vektor fuer synthetische rekombinate |
-
1978
- 1978-12-18 FR FR7835588A patent/FR2444713A1/fr active Granted
-
1979
- 1979-12-12 CH CH1099879A patent/CH646456A5/fr not_active IP Right Cessation
- 1979-12-18 OA OA56977A patent/OA06416A/xx unknown
- 1979-12-18 BE BE2/58277A patent/BE880670A/fr not_active IP Right Cessation
- 1979-12-18 DE DE19792950995 patent/DE2950995A1/de active Granted
- 1979-12-18 GB GB7943491A patent/GB2034323B/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| FR2444713B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1981-02-06 |
| GB2034323A (en) | 1980-06-04 |
| FR2444713A1 (fr) | 1980-07-18 |
| BE880670A (fr) | 1980-06-18 |
| OA06416A (fr) | 1981-09-30 |
| GB2034323B (en) | 1983-01-12 |
| CH646456A5 (fr) | 1984-11-30 |
| DE2950995A1 (de) | 1980-07-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2950995C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| DE3049831C2 (de) | Vektoren enthaltend eine f}r das Oberfl{chenantigen des Hepatites B-Virus kodierende Nucleotidsequenz, Verwendung dieser Vektoren zur Herstellung von Peptiden, Impfstoffe enhaltend dabei erhaltende Peptide als Antigen | |
| DE69518910T2 (de) | Verfahren zur herstellung von viralen vektoren von mindestens 20kb durch intermolekulare homologe rekombination in einer prokaryotischen zelle | |
| DE3072205T2 (de) | Dns-transfer-vektor, damit transformierter wirt, impfstoff und ihre herstellung. | |
| DE2915082C3 (de) | Verfahren und Verwendung eines Reagenzsatzes zum Nachweis und zur Charakterisierung von Nukleinsäuren und ihren Sequenzen | |
| DE69637156T2 (de) | Dna-molekül, herstellung und verwendung in der gentherapie | |
| DE69731939T2 (de) | Isolierung von einzelsträngigen nukleinsäuren | |
| Blattner et al. | Charon phages: safer derivatives of bacteriophage lambda for DNA cloning | |
| DE3752253T2 (de) | Rekombiniertes Alzheimer Amyloid-Protein. | |
| DE69217501T2 (de) | Verfahren zur feststellung der anzahl eines bestimmten dns fragments von interesse bei der enzymatischen amplifikation von dns | |
| DE69534902T2 (de) | Rekombinanter viraler DNS Vektor zur Transfektion tierischer Zellen | |
| DE69011101T2 (de) | Methoden zur in vitro-dna-amplifikation, zum genomischen klonieren und zur genkartierung. | |
| DD147855A5 (de) | Verfahren zur erzeugung mindestens eines hbv-antigenwirkung aufweisenden polypeptids | |
| DD203071A5 (de) | Verfahren zur herstellung von rekombinant-dna-molekuele | |
| DE69839403T2 (de) | Adenovirale vektoren und eine methode zur reduktion von homologer rekombination | |
| CH621147A5 (en) | Process for obtaining a cell culture which produces a desired polypeptide by genetic modification of microorganisms | |
| EP2862935B1 (de) | Minicircles mit Viralen Expressionskassetten und Ihre Verwendung zur Transformation von Zellen zur Erzeugung Rekombinanter Viren oder Viraler Genvektoren | |
| DE69013811T2 (de) | Verfahren zur Herstellung von antiviralem Protein unter Benützung von E.coli-Transformant, das Gen, das für dieses Protein kodiert und E.coli-Vektor benützt in diesem Verfahren. | |
| DE69828167T2 (de) | Rekombinante adenovirale vektoren, die eine spleissequenz enthalten | |
| DE3485834T2 (de) | Verfahren zum bestimmen von nukleinsaeuresequenzen. | |
| EP0279460A1 (de) | Virusantigen, Verfahren zu seiner Gewinnung und Anwendung in Diagnose und Therapie (Impfstoff) | |
| DE69122098T2 (de) | Methoden zur verhinderung von viralen replikationen | |
| EP0227064A1 (de) | Verfahren zur Verbesserung der Expression von Eukaryontenprotein | |
| DE69231143T2 (de) | Spezifische Nukleotidsequenz enthaltender Masernvirusvakzinstamm und Verfahren zu seiner absoluten Identifizierung | |
| DE69506691T2 (de) | Expressionskassette, die einen aus dem Schizosaccharomyces pombe-Pho4-Gene stammenden Promotor enthält |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8110 | Request for examination paragraph 44 | ||
| 8128 | New person/name/address of the agent |
Representative=s name: VOSSIUS, V., DIPL.-CHEM. DR.RER.NAT. TAUCHNER, P., |
|
| 8128 | New person/name/address of the agent |
Representative=s name: KELLER, G., DIPL.-BIOL.UNIV. DR.RER.NAT., PAT.-ANW |
|
| D2 | Grant after examination | ||
| 8364 | No opposition during term of opposition |